99mTc-labeling of a hydrazinonicotinamide-conjugated vitronectin receptor antagonist useful for imaging tumors

Bioconjugate Chemistry

Volumn 12, Issue 4, 2001, Pages 624-629

  Liu, S ^a   Edwards, D S ^a   Ziegler, M C ^a   Harris, A R ^a   Hemingway, S J ^a   Barrett, J A ^a  

^a DUPONT COMPANY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHROMATOGRAPHIC ANALYSIS; COMPLEXATION; TIN COMPOUNDS;

ARG GLY ASPS; BENZENESULFONIC ACID; LABELINGS; LIGAND COMPLEXES; MACROSCOPIC LEVELS; RADIO-HPLC; RADIOMETRICS; RECEPTOR ANTAGONISTS; TECHNETIUM-; VITRONECTIN;

BINDING ENERGY;

CYCLOPEPTIDE; DIAGNOSTIC AGENT; DRUG DERIVATIVE; HYDRAZINE DERIVATIVE; HYDRAZINO NICOTINAMIDE; NICOTINAMIDE; PEPTIDE; RADIOISOTOPE; RP593; TECHNETIUM; TECHNETIUM COMPLEX; VITRONECTIN RECEPTOR;

ARTICLE; BINDING COMPETITION; CHEMISTRY; DRUG ANTAGONISM; DRUG STABILITY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; METABOLISM; NEOPLASM; PHYSIOLOGY; PLACENTA; SCINTISCANNING; SYNTHESIS;

BINDING, COMPETITIVE; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CHROMATOGRAPHY, LIQUID; DRUG STABILITY; HUMANS; HYDRAZINES; MASS SPECTROMETRY; NEOPLASMS; NIACINAMIDE; ORGANOTECHNETIUM COMPOUNDS; PEPTIDES; PEPTIDES, CYCLIC; PLACENTA; RADIOISOTOPES; RECEPTORS, VITRONECTIN; TECHNETIUM;

EID: 0034742826     PISSN: 10431802     EISSN: None     Source Type: Journal    
DOI: 10.1021/bc010012p     Document Type: Article

References (49)

1. 99mTc
2. Recent developments of Tc-99m-labeled peptide-based radiopharmaceuticals: A review
3. Imaging infection/inflammations
4. 99mTc-labeled small peptides as diagnostic radiopharmaceuticals
5. Therapeutic radiopharmaceuticals
6. Potential technetium small molecule radiopharmaceuticals
7. Radiolabeled agents (non-technetium) for diagnostic imaging
8. Receptor targeting for tumor localization and therapy with radiopeptides
9. Radiopharmaceuticals for the visualization of infectious and inflammatory lessions
10. Radio-labeled receptor-binding peptides: A new class of radiopharmaceuticals
11. 99mTc using aminocarboxylates as co-ligands
12. 99mTc-chelator-peptide conjugates
13. 99mTc-chelator-peptide conjugates
14. 99mTc
15. 99mTc
16. 99mTc
17. 99mTc-labeling hydrazones of a hydrazinonicotinamide conjugated cyclic peptide
18. Technetium complexes of a hydrazinonicotinamide-conjugated cyclic peptide and 2-hydrazinopyridine: Synthesis and characterization
19. RP463: A stabilized technetium-99m complex of a hydrazino nicotinamide conjugated chemotactic peptide for infection imaging
20. Leukotriene B4 antagonists modified with amino acid "east end" and technetium-99m chelators for imaging of sites of inflammation and infection
21. The rapid detection of inflammation and infection using Tc-99m labeled LTB4 antagonists
22. 4 antagonist which incorporates the ligand into the binding site
23. 2 formulation for DMP444: A new radiopharmaceutical for thrombus imaging
24. 111In complexes of cyclic RGD peptide antagonists of the integrin αvβ3
25. 99mTc-labeled αvβ3/αvβ5 antagonist, rapidly detects spontaneous tumors in mice and dogs
26. Structural and functional aspect of RGD-containing cyclic pentapeptides as highly potent and selective integrin αvβ3 antagonists
27. The Arg-Gly-Asp binding domain of the vitronectin receptor
28. Angiogenesis in cancer, vascular, rheumatoid and other disease
29. Biochemical interactions of tumor cells with the basement membrance
30. Mechanism of angiogenesis in vascular disorders: Potential therapeutic targets
31. Tumor angiogenesis correlates with metastatic disease, N-myc-amplification, and poor outcome in human neuroblastoma
32. Angiogenesis and colonization in tumor metastatic process: Basis and applied advances
33. Angiogenesis, assessed by platelet/endothelial cell adhesion molecule antibodies, as indicator of node metastases and survival in breast cancer
34. Tumor interactions with the vasculature: Angiogenesis and tumor metastasis
35. Vascular integrin αvβ3: A new prognostic indicator in breast cancer
36. Clinical applications of angiogenic growth factors and their inhibitors
37. Angiogenesis and antiangoegenesis: Perspectives for the treatment of solid tumors
38. Tumor angiogenesis-new drug on the block
39. Integrin αvβ3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels
40. Integrin antagonists and other low molecular weight compounds as inhibitors of angiogenesis: New drugs in cancer therapy
41. Stereoisomeric peptide libraries and peptidomimetics for designing selective inhibitors of the αvβ3 integrin for a new cancer therapy
42. Identification and invivo efficacy of small molecule antagonists of integrin αvβ3 (the vitronectin receptor)
43. An antagonist of integrin αvβ3 prevents maturation of blood vessels during embryonic neovascularization
44. Arg-Gly-Asp constrained within cyclic pentapeptides strong and selective inhibitors of cell adhension to vitronectin and laminin fragment P1
45. RGD-peptides for tumor targeting: Biological evaluation of radioiodinated analogues and introduction of a novel glycosylated peptide with improved biokinetics
46. Radiolabeled αvβ3 integrin antagonists: A new class of tracers for tumor imaging
47. 99mTc-labeled bioconjugates